Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis

Journal of Rheumatology

Volumn 31, Issue 11, 2004, Pages 2236-2241

  Franck, Helmut ^a,c   Meurer, Thomas ^a   Hofbauer, Lorenz Christian ^b  

^a Center of Rheumatology   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c Rheumatologie ^*  (Germany)

Author keywords

Ankylosing spondylitis; Osteoporosis; Osteoprotegerin

Indexed keywords

BIOCHEMICAL MARKER; ESTRADIOL; HORMONE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TESTOSTERONE;

ADULT; AGE DISTRIBUTION; ANKYLOSING SPONDYLITIS; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ESTRADIOL BLOOD LEVEL; EVALUATION; FEMALE; FEMUR; FEMUR NECK; HIP; HORMONE BLOOD LEVEL; HUMAN; INFLAMMATION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIODIAGNOSIS; TESTOSTERONE BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; BONE AND BONES; BONE DENSITY; ESTRADIOL; FEMALE; GLYCOPROTEINS; GONADAL STEROID HORMONES; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TESTOSTERONE;

EID: 7544234549     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Reid DM, Nicoll JJ, Kennedy NS, Smith MA, Tothill P, Nuki G. Bone mass in ankylosing spondylitis. J Rheumatol 1986;13:932-5.
2. Mitra D, Elvins DM, Spenden DJ, Collins AJ. The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatology Oxford 2000;39:85-9.
3. Ralston SH, Urquhart GD, Brzeski M, Sturrock RD. Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. BMJ 1990;300:563-5.
4. Will R, Palmer R, Bhalla AK, Ring F, Calin A. Osteoporosis in early ankylosing spondylitis: a primary pathological event? Lancet 1989;2:1483-5.
5. Devogelaer JP, Maldague B, Malghem J, Nagant de Deuxchaisnes C. Appendicular and vertebral bone mass in ankylosing spondylitis. A comparison of plain radiographs with single- and dual- photon absorptiometry and with quantitative computed tomography. Arthritis Rheum 1992;35:1062-7.
6. Mitra D, Ring EFJ, Bhalla AK, Collins AJ. Osteoporosis associated with ankylosing spondylitis. In: Ring EFJ, editor. Current research in osteoporosis and bone mineral measurement. London: British Institute of Radiology; 1994:42-3.
7. Franck H, Keck E. Serum osteocalcin and vitamin D metabolites in patients with ankylosing spondylitis. Ann Rheum Dis 1993;52:343-6.
8. Juanola X, Mateo L, Nolla JM, Roig-Vilaseca D, Campoy E, Roig-Escofet D. Bone mineral density in women with ankylosing spondylitis. J Rheumatol 2000;27:1028-31.
9. Ekenstam EA, Ljunghall S, Hallgren R. Serum osteocalcin in rheumatoid arthritis and other inflammatory arthritides: relation between inflammatory activity and the effect of glucocorticoids and remission inducing drugs. Ann Rheum Dis 1986;45:484-90.
10. Sheehan NJ, Slavin BM, Kind PR, Mathews JA. Increased serum alkaline phosphatase activity in ankylosing spondylitis. Ann Rheum Dis 1983;42:563-5.
11. Siede WH, Seiffert UB, Merle S, Goll HG, Oremek G. Alkaline phosphatase isoenzymes in rheumatic diseases. Clin Biochem 1989;22:121-4.
12. Marhoffer W, Stracke H, Masoud I, et al. Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis. Ann Rheum Dis 1995;54:556-9.
13. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
14. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329-37.
15. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12.
16. Quinn JM, Elliott J, Gillespie MT, Martin TJ. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998;139:4424-7.
17. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998;188:997-1001.
18. Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999;145:527-38.
19. Jimi E, Akiyama S, Tsurukai T, et al. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 1999;163:434-42.
20. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-57.
21. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:3618.
22. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Disease Activity Index. J Rheumatol 1994;21:2286-91.
23. Calin A, Garret S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath ankylosing spondylitis functional index. J Rheumatol 1994;21:2281-5.
24. MacKay K, Mack C, Brophy S, Calin A. The Bath ankylosing spondylitis radiology index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum 1998;41:2263-70.
25. Franck H, Munz M, Schener M. Evaluation of dual-energy X-ray absorptiometry bone mineral measurement - comparison of a single-beam and fan-beam design: the effect of osteophytic calcification on spine bone mineral density. Calcif Tissue Int 1995;56:192-5.
26. Franck H, Munz M, Scherrer M. Bone mineral density of opposing hips using dual energy X-ray absorptiometry in single-beam and fan-beam design. Calcif Tissue Int 1997;61:445-7.
27. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 2001;86:3162-5.
28. Kotake S, Udagawa N, Hakoda M, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001;44:1003-12.
29. Grisar J, Bernecker PM, Aringer M, et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 2002;29:1430-6.
30. Golmia RP, Sousa BD, Scheinberg MA. Increased osteoprotegerin and decreased pyridinoline levels in patients with ankylosing spondylitis: comment on the article by Gratacos et al. Arthritis Rheum 2002;46:3390-1.
31. Khosla S, Arrighi HM, Melton LJ, et al. Correlates of osteoprotegerin levels in women and men. Osteoporos Int 2002;13:394-9.
32. Yano K, Tsuda E, Washida N, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999;14:518-27.
33. Borman P, Bodur H, Bingöl N, Bingöl S, Bostan EE. Bone mineral density and bone turnover markers in a group of male ankylosing spondylitis patients: relationship to disease activity. J Clin Rheumatol 2001;7:315-21.
34. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001;86:631-7.
35. Seck T, Diel T, Bismar H, Ziegler R, Pfeilschifter J. Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. Eur J Endocrinol 2001;145:199-205.
36. Straub RH, Struharova S, Schölmerich J, Harle P. No alterations of serum levels of adrenal and gonadal hormones in patients with ankylosing spondylitis. Clin Exp Rheumatol 2002;20 Suppl 28:S52-99.
37. Feuerherm AJ, Borset M, Seidel C, et al. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand J Rheumatol 2001;30:229-34.
38. Hofbauer LC, Heufelder AE. The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum 2001;44:253-9.
39. MacDonald AG, Birkinshaw G, Durham B, Bucknall RC, Fraser WD. Biochemical markers of bone turnover in seronegative spondyloarthropathy: relationship to disease activity. Br J Rheumatol 1997;36:50-3.
40. Toussirot E, Ricard-Blum S, Dumoulin G, Cedoz JP, Wendling D. Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis. Rheumatology 1999;38:21-7.
41. Lange U, Jung O, Teichmann J, Neeck G. Relationship between disease activity and serum levels of vitamin D metabolites and parathyroid hormone in ankylosing spondylitis. Osteoporos Int 2001;12:1031-5.